Immuron Reports Strong FY25 Sales Growth and Key Clinical Milestones, Outlines Positive FY26 Outlook

summarizeSummary

Immuron Ltd reported strong FY25 financial results with significant revenue growth and improved EBITDA, alongside critical clinical advancements including FDA IND approval and positive Phase 2 data, setting a positive outlook for FY26.

check_boxKey Events

• Strong FY25 Financial Performance

  Global sales revenue increased by 49% to $7.3 million, with EBITDA (ex-R&D) improving by $2.1 million, moving towards breakeven.

• Key Clinical and Regulatory Milestones Achieved

  Secured FDA IND approval for IMM-529 and reported statistically significant Phase 2 results for Travelan®.

• Positive FY26 Outlook and Pipeline Progress

  Anticipates continued year-over-year sales growth and progression towards EBITDA breakeven, with upcoming 1H 2026 milestones for IMM-986, Travelan®, and IMM-529.

• New Product Launch

  Launched ProIBS® in Australia, expanding its commercial product portfolio for IBS symptoms.

auto_awesomeAnalysis

Immuron Ltd, a micro-cap biopharmaceutical company, presented a comprehensive update highlighting significant progress across its financial performance and clinical pipeline. The company achieved substantial revenue growth in FY25, improved its EBITDA, and secured key regulatory and clinical milestones, including FDA IND approval for IMM-529 and positive Phase 2 results for Travelan®. The outlook for FY26 includes continued sales growth and further advancement of its drug candidates, positioning the company for potential future value creation.